×
About 119,428 results

ALLMedicine™ Melanoma Center

Research & Reviews  56,855 results

A prospective study of cancer-related benefit finding in uveal melanoma patients.
https://doi.org/10.1007/s10865-020-00175-w
Journal of Behavioral Medicine; Herts KL, Jorge-Miller A et. al.

Sep 17th, 2020 - Little is known about contributors to the psychosocial impact of uveal melanoma, a rare cancer. Predictors and outcomes of benefit finding, a potentially favorable outcome, were investigated. Adults (n = 107) completed assessments prior to diagnos...

Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma.
https://doi.org/10.1158/2326-6066.CIR-19-0894
Cancer Immunology Research; Faridi P, Woods K et. al.

Sep 17th, 2020 - Antigen recognition by CD8+ T cells is governed by the pool of peptide antigens presented on the cell surface in the context of HLA class I complexes. Studies have shown not only a high degree of plasticity in the immunopeptidome, but also that a ...

Neoantigen-specific CD4+ T-cell response is critical for the therapeutic efficacy of cr...
https://doi.org/10.1136/jitc-2019-000421
Journal for Immunotherapy of Cancer; Peng P, Hu H et. al.

Sep 17th, 2020 - Traditional tumor thermal ablations, such as radiofrequency ablation (RFA) and cryoablation, can result in good local control of tumor, but traditional tumor thermal ablations are limited by poor long-term survival due to the failure of control of...

Sentinel lymph node biopsy is associated with increased cost in higher risk thin melanoma.
https://doi.org/10.1002/jso.26225
Journal of Surgical Oncology REFERENCES; Aiken TJ, Stahl CC et. al.

Sep 17th, 2020 - National Comprehensive Cancer Network guidelines recommend that sentinel lymph node biopsy (SLNB) be discussed with patients with thin melanoma at higher risk for lymph node metastasis (T1b or T1a with positive deep margins, lymphovascular invasio...

PRAME Expression in 155 Cases of Metastatic Melanoma.
https://doi.org/10.1111/cup.13876
Journal of Cutaneous Pathology; Gradecki SE, Slingluff CL et. al.

Sep 17th, 2020 - PRAME is a promising immunohistochemical marker in distinguishing benign from malignant primary cutaneous melanocytic lesions and lymph node deposits. We hypothesize that PRAME may also reliably identify melanoma metastases that are clinically det...

see more →

Guidelines  177 results

ESMO consensus conference recommendations on the management of locoregional melanoma: u...
https://doi.org/10.1016/j.annonc.2020.07.005
Annals of Oncology : Official Journal of the European Society for Medical Oncology; Michielin O, van Akkooi A et. al.

Aug 8th, 2020 - The European Society for Medical Oncology (ESMO) held a consensus conference on melanoma on 5-7 September 2019 in Amsterdam, The Netherlands. The conference included a multidisciplinary panel of 32 leading experts in the management of melanoma. Th...

ESMO consensus conference recommendations on the management of metastatic melanoma: und...
https://doi.org/10.1016/j.annonc.2020.07.004
Annals of Oncology : Official Journal of the European Society for Medical Oncology; Keilholz U, Ascierto PA et. al.

Aug 8th, 2020 - The European Society for Medical Oncology (ESMO) held a consensus conference on melanoma on 5-7 September 2019 in Amsterdam, The Netherlands. The conference included a multidisciplinary panel of 32 leading experts in the management of melanoma. Th...

ASCO20 Virtual Scientific Program Showcases the Latest Advances in Melanoma Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200224/full/
ASCO Daily News;

Jun 24th, 2020 - The ASCO20 Virtual Scientific Program featured a range of studies showcasing the latest advances and clinical breakthroughs in melanoma research.

see more →

Drugs  61 results see all →

Clinicaltrials.gov  59,397 results

A prospective study of cancer-related benefit finding in uveal melanoma patients.
https://doi.org/10.1007/s10865-020-00175-w
Journal of Behavioral Medicine; Herts KL, Jorge-Miller A et. al.

Sep 17th, 2020 - Little is known about contributors to the psychosocial impact of uveal melanoma, a rare cancer. Predictors and outcomes of benefit finding, a potentially favorable outcome, were investigated. Adults (n = 107) completed assessments prior to diagnos...

Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma.
https://doi.org/10.1158/2326-6066.CIR-19-0894
Cancer Immunology Research; Faridi P, Woods K et. al.

Sep 17th, 2020 - Antigen recognition by CD8+ T cells is governed by the pool of peptide antigens presented on the cell surface in the context of HLA class I complexes. Studies have shown not only a high degree of plasticity in the immunopeptidome, but also that a ...

Neoantigen-specific CD4+ T-cell response is critical for the therapeutic efficacy of cr...
https://doi.org/10.1136/jitc-2019-000421
Journal for Immunotherapy of Cancer; Peng P, Hu H et. al.

Sep 17th, 2020 - Traditional tumor thermal ablations, such as radiofrequency ablation (RFA) and cryoablation, can result in good local control of tumor, but traditional tumor thermal ablations are limited by poor long-term survival due to the failure of control of...

Sentinel lymph node biopsy is associated with increased cost in higher risk thin melanoma.
https://doi.org/10.1002/jso.26225
Journal of Surgical Oncology REFERENCES; Aiken TJ, Stahl CC et. al.

Sep 17th, 2020 - National Comprehensive Cancer Network guidelines recommend that sentinel lymph node biopsy (SLNB) be discussed with patients with thin melanoma at higher risk for lymph node metastasis (T1b or T1a with positive deep margins, lymphovascular invasio...

PRAME Expression in 155 Cases of Metastatic Melanoma.
https://doi.org/10.1111/cup.13876
Journal of Cutaneous Pathology; Gradecki SE, Slingluff CL et. al.

Sep 17th, 2020 - PRAME is a promising immunohistochemical marker in distinguishing benign from malignant primary cutaneous melanocytic lesions and lymph node deposits. We hypothesize that PRAME may also reliably identify melanoma metastases that are clinically det...

see more →

News  2,837 results

ASCO20 Virtual Scientific Program Showcases the Latest Advances in Melanoma Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200224/full/
ASCO Daily News;

Jun 24th, 2020 - The ASCO20 Virtual Scientific Program featured a range of studies showcasing the latest advances and clinical breakthroughs in melanoma research.

Adjuvant pembrolizumab confers durable RFS benefit in resected stage III melanoma
https://www.healio.com/hematology-oncology/melanoma-skin-cancer/news/online/{17cd85c5-d78f-4354-9228-85262589c9eb}/adjuvant-pembrolizumab-confers-durable-rfs-benefit-in-resected-stage-iii-melanoma

May 29th, 2020 - Adjuvant pembrolizumab taken for up to 1 year conferred a durable, clinically meaningful RFS benefit for patients with resected high-risk stage III melanoma, according to study results presented during the ASCO20 Virtual Scientific Program.

Long-Term Benefit of Dabrafenib Plus Trametinib in Melanoma Confirmed in 5-Year Follow-Up of COMBI-AD Study
https://www.targetedonc.com/view/long-term-benefit-of-dabrafenib-plus-trametinib-in-melanoma-confirmed-in-5-year-follow-up-of

May 29th, 2020 - The long-term benefit of adjuvant dabrafenib (Tafinlar) plus trametinib (Mekinist) as treatment of patients with resected, stage III BRAF V600E/K-mutant melanoma were validated by 5-year data from the phase 3 COMBI-AD study, according to a present...

see more →

Patient Education  101 results see all →